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Guidelines for Authors
Acta Cytologica is a bimonthly published journal that aims to cover all aspects within the area of both clinical cytology and cytopathology. It furthers the understanding of cytopathologic processes and facilitates the translation of current research into clinical practice. As the official journal of the International Academy of Cytology and affiliated to over 50 cytology societies around the world, Acta Cytologica evaluates new and existing diagnostic applications of scientific advances as well as their clinical correlation. The journal features Original Papers (Fine Needle Aspiration, Gynecologic Cytopathology, Nongynecologic Cytopathology, Techniques, Molecular Techniques), Novel Insights from Clinical Practice (formerly Case Reports), Letters to the Editor and Reviews. Criteria for acceptance are quality, originality, and clarity. Acta Cytologica will not consider papers that are either preliminary or purely descriptive. Reports on clinical cases are accepted only if they provide novel insight into unresolved problems of cytology and cytopathology. All articles are subject to editorial review.
Submission
Only original papers written in English are considered. Manuscripts should be submitted online using the online submission website at www.karger.com/acy (the preferred word-processing package is MSWord ® ). Before submitting your manuscript, you are encouraged to review the detailed guidelines at www.karger.com/ acy_guidelines for specific directions as how to get a manuscript ready for submission. 
Conditions
All manuscripts must be accompanied by a covering letter signed on behalf of all authors verifying that all the authors were active participants. Assurance should be given that the manuscript is original and not under simultaneous consideration for publication in another journal. Please provide complete financial disclosure information. Presentation of manuscripts should conform with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see N Engl J Med 1997; 336:309-315) . All articles will undergo an in-depth peer-review process. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Acta Cytologica and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the authors' responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications. Signed permission forms from the copyright holders and original authors for all previously published tables or figures must be provided.
Sections
Original Paper (Fine Needle Aspiration, Gynecologic Cytopathology, Nongynecologic Cytopathology, Techniques, Molecular Techniques) : Submitted manuscripts should be fully documented reports of original research. They must describe significant and original observations. Review: Potential authors are asked to contact the Editor-in-Chief before submitting a paper in order to avoid clashes with other pending reviews. Letter to the Editor: Letters to the Editor concerning articles published in Acta Cytologica may be submitted for publication. They should not be more than one printed page in length. If accepted, the authors of the articles concerned will be given the opportunity to reply. Novel Insights from Clinical Practice (formerly Case Reports): the publication space available for case reports is very limited. The journal only considers case reports with significant new insights or with an extremely unusual and memorable course. Highlighted boxes containing one or two bullet points on 'Established facts' (what is already known) and 'Novel insights' (what new information has been gained) are required and should be placed on the first page of the report. These should be selected so as to reinforce the novelty of the clinical observation.
Arrangement
General: Manuscripts should be written in English and be as concise as possible. The length of the text should be limited to approximately 3,000 words, pages numbered consecutively, starting with the title page, and continuing in the following order: abstract and key words, body of text, references, figure legends and tables. Use generic names of drugs when possible. For any trade name cited, capitalize the first letter, and include the manufacturer's name and location (city, state/province, country). Express weights and measures in metric values. Acknowledge any presentation at a national or international medical society and any substantive financial support. Title page: The first page of each paper should indicate the title, the authors' names, the institute(s) where the work was conducted, and a short title for use as running head. Limit the number of authors to 6. If more than 6 authors contributed significantly to the article, the editorial office will consider including their names upon request. Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as an e-mail address. 
Color Illustrations
For all manuscripts accepted, authors will be charged CHF 500.00 for each color page published in the print version of the journal. Several color illustration may be placed onto one color page. When the illustration appears in black and white in the printed version, the authors will not be charged a fee. In the online version all figures submitted in color will appear in color at no charge to the author. Referring to colors in the text and figure legends should be avoided. We recommend using symbols, instead of color, for charts and graphs.
Ethics
Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute's committee on human research and thus meets the standards of the Declaration of Helsinki in its revised version of 1975 and its amendments of 1983 , 1989 , and 1996 [JAMA 1997 277:925-926] . Information suitable to Fax +41 61 306 12 34 E-Mail karger@karger.ch www.karger.com © 2012 S. Karger AG, Basel
The Guidelines for Authors are available at: www.karger.com/acy_Guidelines reveal the subject's identity is to be avoided. Further, authors should also state that animal experiments conform to institutional standards. Copies of these guidelines and policy statements must be available for review by the editors if necessary.
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All forms of funding and support, including that from companies, as well as any potential competing financial interests should be acknowledged in the cover letter to the editors when applicable. The statement has to be listed at the end of the article.
Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.
Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).
Author's Choice
TM
Karger's Author's Choice TM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www. karger.com. The option is available for a onetime fee of CHF 3000.-, which is a permissible cost in a grant allocation. More information can be found at www.karger. com/authors_choice.
NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author's Choice TM service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH's Public Access Policy is available at http://publicaccess.nih.gov/FAQ.htm#a1.
Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution's servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher's version, and must acknowledge the publisher's copyright. Authors selecting Karger's Author's Choice TM feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.
Copy Editing
All manuscripts accepted for publication by Karger are subject to copy editing. Changes introduced by the copy editor and/or questions will be marked in the manuscript so please be sure to check the proofs against the manuscript. The copy edited manuscript will be returned along with the proofs.
Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer's errors, are charged to the author. No page proofs are supplied.
Reprints
An order form and a price list are sent with the proofs. Orders submitted after the release of an article in print are subject to considerably higher prices.
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The Henry Ford Department of Pathology and Laboratory Medicine is seeking a senior pathologist to lead the Cytopathology Division. The Henry Ford Health System, Detroit, is the largest healthcare delivery system in Southeast Michigan and distinguished as a recently named winner of the 2011 Malcolm Baldrige national quality award. The Pathology Department is further recognized as the world's leading Lean managed laboratory enterprise with an integrated service line overseeing laboratory testing at 5 system hospitals, 30 clinic delivery sites, and a growing outreach program. The Department is composed of 42 senior staff pathologists and clinical scientists, complemented by 750 technical staff, with case volumes of 12 million clinical laboratory tests, 80,000 surgical and 85,000 cytology specimens. Cytopathology is a Core Laboratory serving all delivery sites that is located at Henry Ford Hospital, a leading US academic medical center and flagship of the health system. The Division Head will report directly to the Chair and oversee the professional operations, regulation and accreditation, quality assurance plan, Lean management culture, education and research initiatives and the cytology fellowship program.
